vida: extract claims from 2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025

- Source: inbox/queue/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -39,3 +39,10 @@ Target trial emulation (real-world data) shows semaglutide associated with signi
 **Source:** Hendershot et al., JAMA Psychiatry 2025
 
 Phase 2 RCT (n=48, 9 weeks) showed dose-dependent effects on alcohol use disorder: small-to-medium effects at 0.25mg escalating to large effect sizes (Cohen d > 0.80) at 0.5mg for heavy drinking days and drinks per drinking day. Laboratory self-administration showed β=−0.48 for grams consumed (p=0.01) and β=−0.46 for peak BrAC (p=0.03). Alcohol craving reduced significantly (β=−0.39, p=0.01). Cigarette consumption in smokers (n=13) also reduced significantly (p=0.005), suggesting broad reward circuit effects.
+
+
+## Supporting Evidence
+
+**Source:** eClinicalMedicine (Lancet) 2025 systematic review and meta-analysis
+
+Meta-analysis of 14 studies (n=5,262,278) shows pooled AUDIT score reduction of −7.81 points (95% CI −9.02 to −6.60), which is clinically meaningful (moves patients from hazardous to non-hazardous drinking). Pooled observational studies show HR 0.64 (95% CI 0.59–0.69) for alcohol-related events — 36% lower rate. Individual RCTs with semaglutide show significant effects, though pooled RCT analysis is non-significant due to heterogeneity (I²=87.5%) and small-sample pooling. Semaglutide and liraglutide showed strongest and most consistent reductions across studies.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -17,3 +17,10 @@ related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
 
 A 9-week double-blind RCT (n=48) demonstrated that semaglutide produces clinically significant reductions in alcohol consumption through the same VTA dopamine reward circuit mechanism that drives its metabolic effects. The trial showed dose-response escalation: small-to-medium effects at 0.25mg (weeks 1-4), but large effect sizes (Cohen d > 0.80) at 0.5mg (weeks 5-8) for both heavy drinking days and drinks per drinking day. Laboratory alcohol self-administration showed medium-large effects (β=−0.48 grams consumed, p=0.01; β=−0.46 peak BrAC, p=0.03). Weekly alcohol craving showed significant reduction (β=−0.39, p=0.01). The dose-response relationship is critical evidence: if this were placebo effect or behavioral confounding, effect size would not systematically increase with dose. The mechanism is biologically grounded—semaglutide suppresses VTA dopamine activity, the same pathway mediating food reward and hedonic eating. Notably, the trial also found significant cigarette reduction in the smoker subgroup (n=13, p=0.005), suggesting broad reward circuit effects beyond alcohol. Limitations: Phase 2 only, 9-week duration, non-treatment-seeking participants with moderate AUD severity, and 1.0mg dose reached only in final week. No abstinence endpoints measured. Phase 3 trials now underway.
+
+
+## Supporting Evidence
+
+**Source:** eClinicalMedicine (Lancet) 2025 systematic review
+
+Meta-analysis confirms semaglutide as best-performing agent for alcohol reduction across 14 studies. The −7.81 point AUDIT reduction represents movement from hazardous to non-hazardous drinking levels. Individual semaglutide RCTs (including Hendershot 2025) each show significant effects, with reductions in drinking days, units per drinking day, and cravings.

inbox/archive/health/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md

@@ -7,9 +7,12 @@ date: 2025
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, alcohol-use-disorder, AUD, meta-analysis, systematic-review, semaglutide, liraglutide, AUDIT, addiction, reward-circuit]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content